MarketCap
Facebook
X
TelegramGeschäftsbericht 2024
hinzugefügt 21.03.2026
Nymox Pharmaceutical Corporation Langfristiger Schuldenstrom 2011-2026 | NYMX
Langfristiger Schuldenstrom Jährlich Nymox Pharmaceutical Corporation
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | - | - | 23 K | - | - | - | - | - | - | - |
Alle Zahlen in USD-Währung
Indikatorenreichweite aus Jahresberichten
| Höchstwert | Mindestwert | Durchschnitt |
|---|---|---|
| 23 K | 23 K | 23 K |
Langfristiger Schuldenstrom anderer Aktien in der Pharmaeinzelhändler
| Name | Langfristiger Schuldenstrom | Preis | % 24h | Marktkapitalisierung | Land | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
3.63 M | - | 2.43 % | $ 254 M |  Germany |
 |
Acorda Therapeutics
ACOR
|
1.59 M | - | -24.86 % | $ 820 K |  USA |
 |
AbbVie
ABBV
|
194 M | $ 208.84 | -2.86 % | $ 369 B | USA |
 |
AbCellera Biologics
ABCL
|
5.82 M | $ 3.52 | 0.28 % | $ 1.05 B |  Canada |
 |
Grifols, S.A.
GRFS
|
117 M | $ 8.24 | -0.12 % | $ 6.83 B |  Spain |
 |
Ascendis Pharma A/S
ASND
|
14.2 M | $ 229.25 | 0.44 % | $ 5 B |  Danmark |
 |
I-Mab
IMAB
|
8.06 M | - | - | $ 866 M |  China |
 |
Aeterna Zentaris
AEZS
|
271 K | - | 5.93 % | $ 314 M | Canada |
 |
Aeglea BioTherapeutics
AGLE
|
625 K | - | - | $ 1.01 B | USA |
 |
Applied Genetic Technologies Corporation
AGTC
|
1.27 M | - | - | $ 26.5 M | USA |
 |
ANI Pharmaceuticals
ANIP
|
1.8 M | $ 74.21 | -2.3 % | $ 1.43 B | USA |
 |
Adverum Biotechnologies
ADVM
|
5.67 M | - | - | $ 86.2 M | USA |
 |
Advaxis
ADXS
|
166 K | - | -9.65 % | $ 45.9 M | USA |
 |
Autolus Therapeutics plc
AUTL
|
4.56 M | $ 1.41 | 2.17 % | $ 375 M |  Britain |
 |
AgeX Therapeutics
AGE
|
181 K | - | -10.17 % | $ 12.2 K | USA |
 |
Cocrystal Pharma
COCP
|
334 K | $ 1.51 | 48.04 % | $ 17 M | USA |
 |
Applied Molecular Transport
AMTI
|
4.64 M | - | - | $ 10.1 M | USA |
 |
AIkido Pharma
AIKI
|
554 K | - | 1.93 % | $ 17.4 M | USA |
 |
Akouos
AKUS
|
671 K | - | 0.23 % | $ 488 M | USA |
 |
Allena Pharmaceuticals
ALNA
|
317 K | - | 3.16 % | $ 1.9 M | USA |
 |
BioMarin Pharmaceutical
BMRN
|
8.57 M | $ 55.5 | -3.04 % | $ 10.6 B | USA |
 |
Alpine Immune Sciences
ALPN
|
756 K | - | - | $ 2.17 B | USA |
 |
Aileron Therapeutics
ALRN
|
48 K | - | 10.36 % | $ 9.8 M | USA |
 |
Arcturus Therapeutics Holdings
ARCT
|
4.21 M | $ 8.03 | 2.29 % | $ 220 M |  Israel |
 |
Adaptive Biotechnologies Corporation
ADPT
|
8.92 M | $ 14.81 | 2.63 % | $ 2.25 B | USA |
 |
Altimmune
ALT
|
256 K | $ 3.34 | 7.05 % | $ 294 M | USA |
 |
BioNTech SE
BNTX
|
45 M | $ 91.18 | 1.97 % | $ 27.2 B | Germany |
 |
Amgen
AMGN
|
135 M | $ 347.94 | -1.51 % | $ 187 B | USA |
 |
Aurinia Pharmaceuticals
AUPH
|
1.07 M | $ 15.61 | 0.9 % | $ 2.1 B | Canada |
 |
Bristol-Myers Squibb Company
BMY
|
202 M | $ 59.6 | -2.45 % | $ 121 B | USA |
 |
Aptose Biosciences
APTO
|
193 K | - | -45.71 % | $ 1.2 M | Canada |
 |
Aptinyx
APTX
|
337 K | - | -39.0 % | $ 4.57 M | USA |
 |
CureVac N.V.
CVAC
|
3.47 M | - | - | $ 867 M | Germany |
 |
BioCryst Pharmaceuticals
BCRX
|
937 K | $ 9.02 | -3.84 % | $ 1.86 B | USA |
 |
Atea Pharmaceuticals
AVIR
|
843 K | $ 5.76 | 1.95 % | $ 469 M | USA |
 |
BeiGene, Ltd.
BGNE
|
20.7 M | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
AVROBIO
AVRO
|
878 K | - | 1083.1 % | $ 745 M | USA |
 |
Cellectis S.A.
CLLS
|
7.7 M | $ 3.41 | 1.19 % | $ 116 M |  France |
 |
Biogen
BIIB
|
80.4 M | $ 177.34 | -3.5 % | $ 26 B | USA |
 |
Axcella Health
AXLA
|
1.59 M | - | -16.42 % | $ 249 M | USA |
 |
Axon Enterprise
AXON
|
9.45 M | $ 412.81 | -2.54 % | $ 31.3 B | USA |